Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.73 |
| ▸ | POLB | P06746 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | HTT | P42858 | 3/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11784892 | 0.88 | KDM4E (0.79) | KDM4EALDH1A1CYP2C9CYP1A2POLB | |
| SCHEMBL13753815 | 0.85 | ALDH1A1 (0.76) | KDM4EALDH1A1CYP2C9CYP1A2POLB | |
| SCHEMBL13753806 | 0.85 | RAB9A (0.82) | KDM4EALDH1A1CYP2C9CYP1A2POLB | |
| SCHEMBL7694742 | 0.84 | KDM4E (0.73) | KDM4EALDH1A1CYP2C9CYP1A2POLB | |
| SCHEMBL978291 | 0.83 | KDM4E (0.71) | KDM4EALDH1A1CYP2C9CYP1A2POLB | |
| SCHEMBL16495997 | 0.83 | KDM4E (0.71) | KDM4EALDH1A1CYP2C9CYP1A2POLB | |
| SCHEMBL1098123 | 0.82 | CYP2C9 (0.73) | KDM4EALDH1A1CYP2C9CYP1A2POLB | |
| SCHEMBL3480459 | 0.82 | KDM4E (0.69) | KDM4EALDH1A1CYP2C9CYP1A2POLB | |
| SCHEMBL1432938 | 0.82 | ALDH1A1 (0.72) | KDM4EALDH1A1CYP2C9CYP1A2POLB | |
| SCHEMBL11786444 | 0.82 | KDM4E (0.69) | KDM4EALDH1A1CYP2C9CYP1A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040186081-A1 | Naaladase inhibitors for treating opioid tolerance | GUILFORD PHARMACEUTICALS INC. | 2004-09-23 | — | — | US | claimed |
| WO-2004078180-A2 | NAALADASE INHIBITORS FOR TREATING OPIOID TOLERANCE | GUILFORD PHARMACEUTICALS INC. (US) | 2004-09-16 | — | — | WO | claimed |
| US-20030036534-A1 | Naaladase inhibitors for treating retinal disorders and glaucoma | EISAI INC. | 2003-02-20 | — | — | US | claimed |
| US-7220780-B2 | Naaladase inhibitors for treating retinal disorders and glaucoma | GUILFORD PHARMACEUTICALS INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220780-B2 | Naaladase inhibitors for treating retinal disorders and glaucoma | GUILFORD PHARMACEUTICALS INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220780-B2 | Naaladase inhibitors for treating retinal disorders and glaucoma | GUILFORD PHARMACEUTICALS INC. (US) | 2007-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186081-A1 | Naaladase inhibitors for treating opioid tolerance | OPRD1, OPRK1, OPRM1 | KDM4E 991/4885ALDH1A1 105/4885CYP2C9 45/4885 |
| US-20030036534-A1 | Naaladase inhibitors for treating retinal disorders and glaucoma | ALDH1A2, GAA, PDE6A | KDM4E 2355/4885ALDH1A1 198/4885CYP2C9 2133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.